Bluntly Zen / Wellness / Research
Cannabis and psychedelic research, in plain English.
Where the science and the law actually stand on cannabis, CBD, psilocybin, MDMA, ketamine, ibogaine and more, with sources for every entry. Built on the Psykhd Education Library and public cannabis research from NIDA, NCCIH, the CDC and the National Academies.
General education, not medical or legal advice. Many substances described here are illegal under federal law and in most states. Talk to a licensed clinician before making health decisions. In a U.S. mental health crisis, call or text 988.
Cannabis
What the science says about cannabis
Approved medicines, the strongest evidence, the 2026 federal changes and the risks worth knowing.
What the research says about medical cannabis
The landmark 2017 National Academies review of more than 10,000 studies found conclusive or substantial evidence that cannabis or cannabinoids help with chronic pain in adults, nausea and vomiting from chemotherapy, and muscle spasticity from multiple sclerosis. For many other uses, including anxiety, PTSD and sleep, the evidence was limited, mixed or missing.
Key points, safety and sources
Key points
- Strongest evidence: chronic pain, chemotherapy-related nausea and MS spasticity.
- Evidence for sleep and anxiety is limited, and most studies are small or short.
- Schedule I rules slowed research for decades; partial rescheduling in 2026 is starting to ease that.
- Dispensary products vary widely from the formulations tested in trials.
Federal status: Schedule I, except FDA-approved products and state-licensed medical marijuana (Schedule III since April 2026)
On Bluntly Zen
Updated October 28, 2026
Cannabis for chronic pain
Chronic pain is the most common reason people use medical cannabis, and it has some of the strongest evidence. The National Academies found substantial evidence that cannabis or cannabinoids reduce chronic pain in adults, though improvements in trials were usually modest. Most of that evidence comes from products containing THC; evidence for CBD alone is much thinner.
Key points, safety and sources
Key points
- Expect modest relief, not a cure; results vary a lot from person to person.
- Many studies used pharmaceutical cannabinoids or standardized products, not dispensary flower.
- Talk to your doctor before combining cannabis with opioids, sedatives or sleep medicines.
Safety
- THC can cause dizziness and sedation, which raises fall risk, especially for older adults.
On Bluntly Zen
Updated October 28, 2026
Cannabis, sleep and anxiety
Many people use cannabis to sleep or to calm down, but the research is thinner than the popularity suggests. The National Academies found moderate evidence of short-term sleep improvement in people whose sleep is disrupted by conditions like sleep apnea, fibromyalgia, chronic pain or multiple sclerosis, and limited evidence that CBD eased anxiety in people with social anxiety during a public-speaking test.
Key points, safety and sources
Key points
- Higher-THC products can trigger or worsen anxiety and paranoia in some people.
- Using cannabis every night for sleep can build tolerance, and stopping can cause temporary trouble sleeping and vivid dreams.
- For ongoing insomnia or anxiety, proven treatments like CBT-I and therapy are worth discussing with a clinician.
On Bluntly Zen
Prescription CBD (Epidiolex)
Epidiolex, a purified CBD oral solution made from the cannabis plant, was approved by the FDA in 2018 for seizures linked to Lennox-Gastaut syndrome and Dravet syndrome, and in 2020 for tuberous sclerosis complex. It is the only FDA-approved drug made from the plant itself.
Key points, safety and sources
Key points
- The doses studied are far higher than what typical store-bought CBD contains.
- Over-the-counter CBD is not FDA-approved, and label accuracy varies.
- Its approval shows CBD's effects depend heavily on dose and purity.
Federal status: Not a controlled substance (removed from scheduling in 2020)
Safety
- Can raise liver enzymes, especially with valproate, so doctors monitor liver tests.
- Interacts with clobazam and other medications processed by the liver.
On Bluntly Zen
Updated October 28, 2026
Prescription THC: dronabinol and nabilone
Synthetic THC medicines have been FDA-approved for decades. Dronabinol (Marinol, Syndros) treats nausea and vomiting from chemotherapy and appetite loss with weight loss in people with AIDS. Nabilone (Cesamet) treats chemotherapy-related nausea.
Key points, safety and sources
Key points
- Usually prescribed when standard anti-nausea drugs haven't worked well enough.
- Effects and side effects resemble THC: drowsiness, dizziness, euphoria and mood changes.
- These are single-molecule drugs, so they contain no CBD or terpenes.
Federal status: Schedule II or III, depending on the product
Safety
- Can impair driving and coordination.
- Use caution with a history of psychosis or heart conditions.
Updated October 28, 2026
Federal rescheduling: where it stands
A final rule published April 28, 2026 moved FDA-approved marijuana products and marijuana covered by a state medical marijuana license to Schedule III. The broader proposal to move all marijuana to Schedule III went through hearings in June and July 2026, but a DEA judge paused the proceeding on Sept. 29, 2026 to consider a new GAO report.
Key points, safety and sources
Key points
- Schedule III recognizes accepted medical use and eases some research and tax rules for covered medical operators.
- Adult-use (recreational) marijuana is still Schedule I under federal law.
- Rescheduling does not make cannabis federally legal or allow carrying it across state lines.
- Executive Order 14370 (December 2025) directed the Justice Department to finish the rulemaking quickly.
Federal status: Partly Schedule III (FDA-approved and state-licensed medical); otherwise Schedule I
On Bluntly Zen
Hemp THC products: the 2026 federal changes
A federal spending law passed in November 2025 redefines hemp. Starting Nov. 12, 2026, cannabinoids that the plant can't produce naturally lose hemp status. Starting Dec. 11, 2026, hemp is measured by total THC, including THCA, and finished products are capped at 0.4 mg of total THC per container.
Key points, safety and sources
Key points
- Most intoxicating hemp products sold today, including delta-8 and many delta-9 gummies and drinks, would no longer qualify as hemp.
- Non-intoxicating CBD products can still qualify if they meet the new total-THC limits.
- States can be stricter: Texas already bans delta-8, delta-10 and most THCA flower.
Federal status: Hemp at 0.3% delta-9 THC or less is legal until the new definition applies
On Bluntly Zen
Cannabis risks worth knowing
Most adults who use cannabis don't run into serious problems, but some risks are well documented: cannabis use disorder, a higher risk of psychosis with frequent high-potency use, cannabinoid hyperemesis syndrome, impaired driving, and harms during pregnancy.
Key points, safety and sources
Key points
- The CDC estimates about 3 in 10 people who use cannabis have cannabis use disorder; risk is higher with daily use and starting young.
- Daily use of high-potency THC is linked to higher rates of psychosis, especially with a personal or family history.
- Cannabinoid hyperemesis syndrome causes repeated severe vomiting in some long-term heavy users; stopping cannabis resolves it.
- THC slows reaction time and coordination. Never drive high.
- Health groups advise avoiding cannabis during pregnancy and breastfeeding.
Safety
- Get help right away for chest pain, fainting, or vomiting you can't stop. For a mental health crisis in the U.S., call or text 988.
On Bluntly Zen
Edibles: delayed effects and accidental poisonings
Edibles take much longer to kick in than smoking or vaping, often 30 minutes to 2 hours, and the effects can last six hours or more. That delay is the most common reason people take too much. Edibles also look like ordinary candy and snacks, and poison centers have reported sharp increases in young children eating them by accident.
Key points, safety and sources
Key points
- Wait at least two hours before taking more.
- Read the label for THC per serving, not per package.
- Store edibles locked up, in original child-resistant packaging, away from children and pets.
Safety
- If a child eats an edible, call Poison Control at 1-800-222-1222 right away, or 911 if they are hard to wake or having trouble breathing.
On Bluntly Zen
CBD: drug interactions and label accuracy
CBD is generally well tolerated, but it is processed by the same liver enzymes as many medications, so it can change their levels in the body. Store-bought CBD is also loosely regulated, and testing has repeatedly found products with more or less CBD than the label says, and sometimes unlisted THC.
Key points, safety and sources
Key points
- Ask a pharmacist before using CBD with blood thinners, seizure medications or other drugs with liver warnings.
- High doses can raise liver enzymes and cause drowsiness or diarrhea.
- Choose products with a current third-party lab report (COA) that matches the batch.
- Full-spectrum CBD can contain enough THC to show up on a drug test.
Federal status: Hemp CBD is federally legal; limits tighten Dec. 11, 2026
On Bluntly Zen
Updated October 28, 2026
Psychedelics
Psychedelics
What's approved, what's under FDA review, where psilocybin is legal, and how to stay safe. None of this is dosing advice.
Federal psychedelic policy in 2026
An executive order signed in April 2026 directed federal agencies to speed review of psychedelic drugs for serious mental illness, including ibogaine compounds. Days later, the FDA gave National Priority Vouchers to three programs: Compass Pathways' COMP360 psilocybin for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder, and Transcend Therapeutics' methylone (TSND-201) for PTSD.
Key points, safety and sources
Key points
- Faster review is not approval. Each drug still has to show it is safe and effective.
- The order also points to Right to Try, which lets some patients with serious conditions ask for investigational drugs that have passed early trials. Drugmakers don't have to agree.
- The FDA also cleared an early study of noribogaine for alcohol use disorder.
Federal status: Schedule I until approved and rescheduled
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Psilocybin therapy for depression
Psilocybin, the active compound in magic mushrooms, is being studied with psychological support for depression. Compass Pathways reported positive Phase 3 results for its COMP360 psilocybin in treatment-resistant depression and is submitting its FDA application on a rolling basis, with completion expected in late 2026. Its April 2026 priority voucher can shorten review once the application is complete.
Key points, safety and sources
Key points
- Not FDA-approved yet. Outside approved state programs it remains illegal.
- In trials, sessions happen in a clinical setting with trained monitors, preparation and follow-up.
- Johns Hopkins and others have published follow-up data suggesting benefits can last months for some people.
- Usona Institute is developing psilocybin for major depressive disorder and also holds a priority voucher.
Federal status: Schedule I
Safety
- Trials usually exclude people with a personal or family history of psychosis or bipolar disorder.
- Psilocybin raises blood pressure and heart rate during a session.
- Frightening or confusing experiences are common, which is why supervision matters.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Psilocybin: where it's legal
Oregon runs a licensed psilocybin services program: adults 21+ can take psilocybin at a licensed service center with a trained facilitator, no prescription needed. Colorado decriminalized personal use for adults 21+ and licenses healing centers. New Mexico passed a medical psilocybin program in 2025, set to launch by the end of 2027. Psilocybin is still Schedule I under federal law.
Key points, safety and sources
Key points
- Oregon: licensed service centers and facilitators, adults 21+.
- Colorado: state-licensed healing centers; personal use decriminalized for adults 21+.
- Some cities have deprioritized enforcement, but that doesn't make sales legal.
- Never carry psilocybin across state lines or through airports.
Federal status: Schedule I
Safety
- Licensed programs screen for health risks before a session. Unlicensed retreats may not.
On Bluntly Zen
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
MDMA-assisted therapy for PTSD
Phase 3 trials sponsored by Lykos Therapeutics tested MDMA combined with talk therapy for PTSD. An FDA advisory panel voted against it in June 2024, and in August 2024 the FDA declined to approve it and asked for another Phase 3 trial. The FDA's response letter was made public in September 2025.
Key points, safety and sources
Key points
- Concerns included how well the trials were blinded, missing data on abuse potential, and how the therapy portion was run.
- In the U.S., MDMA is available only in clinical trials.
- A related compound, methylone, is being developed for PTSD by Transcend Therapeutics.
Federal status: Schedule I
Safety
- MDMA raises heart rate, blood pressure and body temperature.
- Street MDMA (Molly) is often mixed with other drugs, sometimes dangerous ones.
- MDMA combined with some antidepressants can cause serotonin syndrome.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Methylone (TSND-201) for PTSD
Methylone is an MDMA-like compound that Transcend Therapeutics is developing as TSND-201 for PTSD. It received an FDA National Priority Voucher in April 2026, and Otsuka agreed to acquire Transcend for about $1.2 billion.
Key points, safety and sources
Key points
- Still in clinical trials and not FDA-approved.
- A priority voucher can shorten FDA review once a complete application is filed.
Federal status: Schedule I
Safety
- Like MDMA, methylone can raise heart rate and blood pressure.
Updated October 28, 2026
Ibogaine for addiction and brain injury
Ibogaine, from the root bark of the African iboga shrub, is being studied for opioid use disorder and other addictions, traumatic brain injury and PTSD. Texas committed $50 million to clinical trials led by UTHealth Houston with UTMB Health. The April 2026 executive order named ibogaine compounds, and the FDA cleared an early study of noribogaine, a related compound, for alcohol use disorder.
Key points, safety and sources
Key points
- Not FDA-approved.
- Some people travel to clinics abroad, where safety standards vary widely.
Federal status: Schedule I
Safety
- Ibogaine can cause dangerous heart rhythm problems (QT prolongation), and deaths have been reported.
- Legitimate studies require medical screening and continuous heart monitoring.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Ketamine infusions for depression
Ketamine, an anesthetic that acts on the brain's NMDA receptors, can ease depression within hours for some people with treatment-resistant depression. IV ketamine for depression is off-label: doctors can prescribe it, but it isn't FDA-approved for that use. Benefits often fade within one to two weeks without repeat treatments or therapy.
Key points, safety and sources
Key points
- Given in a clinic with medical monitoring.
- Often paired with therapy to help benefits last.
- Insurance coverage for IV ketamine is limited.
Federal status: Schedule III
Safety
- Can cause dissociation, higher blood pressure and nausea.
- Ketamine can be misused, and frequent use can damage the bladder.
- The FDA has warned about compounded at-home ketamine products, which have less oversight.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Esketamine (Spravato)
Spravato, an esketamine nasal spray, was approved by the FDA in 2019 for treatment-resistant depression alongside an oral antidepressant, and in January 2025 as a standalone treatment. Because it can cause sedation and dissociation, it's given only at certified clinics, where patients are observed for at least two hours.
Key points, safety and sources
Key points
- Also approved, with an oral antidepressant, for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior.
- Patients shouldn't drive until the next day after a dose.
- Available only through a restricted safety program (REMS).
Federal status: Schedule III
Safety
- Common effects include dissociation, dizziness, nausea and higher blood pressure.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Psychedelic safety and harm reduction
Outside approved programs and clinical trials, psychedelics are illegal in most places, and unregulated products can be mislabeled or contaminated. For anyone who chooses to use them anyway, lowering risk starts with health screening, a safe setting and a sober sitter. Bluntly Zen does not give dosing advice.
Key points, safety and sources
Key points
- Higher risk: a personal or family history of psychosis or bipolar disorder, heart conditions, and pregnancy.
- Risky combinations: lithium with psychedelics has been linked to seizures, MDMA with some antidepressants can cause serotonin syndrome, and alcohol or other drugs add risk.
- Drug-checking kits can detect some adulterants.
- The Fireside Project offers free peer support during and after psychedelic experiences.
Safety
- In an emergency, call 911. For a mental health crisis in the U.S., call or text 988.
Updated October 28, 2026
Novel therapies
Novel therapies beyond medication
Non-drug treatments from the Psykhd Education Library that are already FDA-approved or cleared.
Transcranial magnetic stimulation (TMS)
TMS uses magnetic pulses to stimulate brain areas involved in mood. It's done in outpatient sessions without anesthesia and has been FDA-approved for major depression since 2008, and more recently cleared for adolescents ages 15 to 21.
Key points, safety and sources
Key points
- In controlled trials, about 4 in 10 patients respond and about a third reach full remission, well above sham treatment.
- Many people who respond keep the benefit for 3 to 12 months.
- Often used when antidepressants haven't worked well enough.
Safety
- Side effects are usually mild, most often scalp discomfort or headache. Seizures are rare.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
Prescription digital therapeutics
Prescription digital therapeutics deliver structured cognitive behavioral therapy through an FDA-authorized smartphone app that a clinician prescribes. Examples include Rejoyn for depression, DaylightRx for anxiety, MamaLift Plus for postpartum depression and SleepioRx for insomnia. By early 2026, roughly a dozen had been cleared or authorized by the FDA.
Key points, safety and sources
Key points
- Medicare created billing codes for this category in late 2024.
- Some major insurers began covering FDA-cleared apps in 2025.
- They're meant to work alongside care from a clinician, not replace it.
Adapted from the Psykhd Education Library (psykhd.com) · Updated October 28, 2026
No entries match that search.
Research centers
Where psychedelic research happens
50 universities and hospitals running psychedelic studies, from the Psykhd Global Research Institution Directory. Check ClinicalTrials.gov for studies that are recruiting.
United States 28
- Johns Hopkins University Studies psilocybin for depression, tobacco dependence and anorexia, with neuroimaging.
- NYU Langone Health Psychedelic medicine center; ran a 2022 psilocybin trial for alcohol use disorder.
- Yale University Studies how psilocybin changes brain structure and its links to reduced depression.
- UC Berkeley Studies psilocybin's effects on cognition and perception; publishes a clinical-trials map.
- UC San Francisco Combines clinical psychedelic trials with translational neuroscience.
- Ohio State University Focuses on underrepresented populations and training future clinicians.
- University of Wisconsin–Madison Scientific, historical and cultural research across about ten active trials.
- University of Texas at Austin Psilocybin, MDMA and ibogaine research for veterans with PTSD, grief and childhood trauma.
- Massachusetts General Hospital / Harvard Studies how psychedelics reshape brain structure and function.
- Icahn School of Medicine at Mount Sinai MDMA-assisted therapy for veterans with PTSD and psilocybin for civilians.
- Emory University Psychedelic-assisted therapy in its cultural and spiritual context.
- Stanford University Ketamine, psilocybin and MDMA for OCD, treatment-resistant depression and PTSD.
- University of Michigan Hub launched in 2022 spanning basic discovery through clinical care.
- University of Colorado Launched in 2024; psychiatric, neurologic and palliative care research with a policy focus.
- Washington University in St. Louis Neuroimaging plus a Phase II/III psilocybin trial site with the Usona Institute.
- University of New Mexico Long research history; current psilocybin, MDMA and ketamine trials.
- University of Washington Usona-sponsored psilocybin trials, including for frontline health workers.
- Columbia University Ketamine for substance use disorders since 2014; psilocybin trial site.
- UC San Diego Pairs trials with fMRI, EEG and cognitive data to study how psychedelics work.
- UC Davis Studies neural plasticity and designs non-hallucinogenic psychedelic analogues.
- Oregon Health & Science University Studies psychedelics, oxytocin and MDMA to strengthen the therapeutic relationship.
- University of Arizona Hosted an early 2006 psilocybin trial for OCD and continues related work.
- University of Alabama at Birmingham NIH-funded psilocybin therapy research for cocaine dependence and smoking cessation.
- Northwestern University Ketamine for brain-injury symptoms and depression around surgery; early psilocybin work.
- University of Minnesota Studies ayahuasca for trauma and the neuroscience of altered states.
- University of Nebraska Medical Center Studies psychedelics for resilience in palliative and serious-illness care.
- VA Greater Los Angeles Healthcare System Part of a multi-site VA network studying MDMA and psilocybin for veterans.
- Brigham and Women's Hospital (Harvard) Launching psilocybin therapy trials for alcohol and opioid use disorders.
Canada 5
- University of British Columbia Psilocybin-assisted therapy for opioid and other substance use disorders.
- McGill University How setting and therapeutic relationships shape outcomes, plus preclinical work.
- University of Toronto Mississauga Open-science, pre-registered psilocybin microdosing trials.
- McMaster University Phase 2 psilocybin-assisted therapy study for cannabis use disorder.
- Queen's University Clinical research on psychedelic-assisted therapies with Providence Care.
Europe 14
- Imperial College London Pioneering psilocybin research; proposed influential brain models such as REBUS.
- King's College London New care models for depression, PTSD and anorexia nervosa.
- University College London First in-human DMT study at UCL, using fMRI and eye-tracking.
- University of Cambridge Building NHS-ready psychedelic treatment protocols.
- University of Exeter Psychology, neuropharmacology and philosophy, including group psilocybin trials.
- University of Manchester Phase II trials pairing psilocybin with structured talking therapy.
- University of Basel LSD for cluster headache, depression and anxiety; compares several compounds.
- University of Zurich Whether psychedelics can reverse patterns behind stress-related mood disorders.
- Geneva University Hospitals Has delivered LSD- and psilocybin-assisted therapy to patients since 2020.
- Radboud University Medical Center Studies ibogaine's heart safety as a potential opioid use disorder treatment.
- Maastricht University Microdosing research with the Beckley Foundation.
- Karolinska Institutet Sweden's first Phase II psilocybin depression trial, with PET/MRI imaging.
- University of Copenhagen Neuroimaging research on psychedelics' brain effects since 2017.
- Østfold Hospital Supported European MDMA-PTSD trials; published an MDMA depression trial.
Asia-Pacific & Latin America 3
- Tel Aviv University Studies brain-mind-body links across two clinical trials.
- Monash University Tests psychedelic therapies within Australia's healthcare system.
- University of São Paulo Studies hallucinogenic compounds for mental health, plus public science communication.
Keep learning
More cannabis and psychedelic libraries
Trusted education libraries we draw on. Government and academic sources come first.
For developers
Research API
A free, read-only JSON API for the entries on this page. No key needed. Responses can be called from any website (CORS enabled) and are cached for 10 minutes. Please credit “Bluntly Zen Research Library” and link back.
| Endpoint | Returns |
|---|---|
GET /api/research | All entries. Filters: topic (cannabis, psychedelics or therapies), status (e.g. FDA-approved, Investigational, Safety), q (text search), limit (1–100), fields (comma-separated, e.g. title,status,summary). |
GET /api/research/{id} | One entry, e.g. /api/research/psilocybin-depression. |
GET /api/research/topics | Topics (cannabis, psychedelics, therapies) with counts, and the status groups. |
GET /api/research/institutions | 50 psychedelic research centers from the Psykhd directory. Filters: region, q. |
GET /api/research/libraries | Trusted cannabis and psychedelic education libraries. Filter: topic. |
Fields: id, topic, title, substance, status, status_group, federal_status, summary, key_points[], safety[], sources[{title,url}], related[{title,url}], credit, updated, url. Every response also includes attribution and disclaimer, which should be shown with the content.
curl "https://www.bluntlyzen.com/api/research?topic=psychedelics&status=FDA-approved"
Limit: 60 requests per minute per IP. Content is general education, not medical or legal advice, and may change as research and laws change; check updated.